← Leaderboards
Maja Diana Neely
Vanderbilt University
$2,145,567
Attributed
$6,700,510
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2016–21$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,700,510 · 3
By mechanism
UH3$5,654,091 · 2
UG3$1,046,419 · 1
Top collaborators
- John Peter Wikswo6 shared
- Kevin C Ess5 shared
- Chaitali Ghosh1 shared
- Damir Janigro1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- F Peter Guengerich$48,178,939
- John Peter Wikswo$17,124,536
- Michael P Stone$20,424,729
- Kevin C Ess$5,903,437
- Donna J Webb$5,224,583
Others in their field
Top investigators on “Blood - Brain Barrier Anatomy”
- Ann M Chahroudi · Emory University$4,494,806
- Sean P Colgan · University Of Colorado Denver$4,334,832
- James A Hoxie · University Of Pennsylvania$3,749,681
- Leslie S Kean · Emory University$3,499,061
- Ya-Chi Ho · Johns Hopkins University$3,352,212
- Mark Roberts Looney · University Of California, San Francisco$3,248,220
Research focus
Blood - Brain Barrier AnatomyDrug EfficacyResponseBrainDisease ModelCellsIn VitroPharmaceutical PreparationsAffectEndothelial CellsNeurovascular UnitFunctional DisorderAstrocytesFda ApprovedClinical TrialsEpilepsyInstitutesEffective TherapyDrug ToxicityEducationBiological ModelsCardiacAnimal ModelDrug Development
Grant awards (6)
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,149,180
UH3 · FY2021 · TR
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,149,938
UH3 · FY2020 · TR
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,142,940
UH3 · FY2020 · TR
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,156,801
UH3 · FY2019 · TR
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,046,419
UG3 · FY2018 · TR
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses$1,055,232
UH3 · FY2016 · TR